These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 27520631)
21. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464 [TBL] [Abstract][Full Text] [Related]
22. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Zhang S; Wang X; Sagawa K; Morris ME Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138 [TBL] [Abstract][Full Text] [Related]
23. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634 [TBL] [Abstract][Full Text] [Related]
24. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). Sim HM; Lee CY; Ee PL; Go ML Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288 [TBL] [Abstract][Full Text] [Related]
25. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
27. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798 [TBL] [Abstract][Full Text] [Related]
28. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901 [TBL] [Abstract][Full Text] [Related]
29. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232 [TBL] [Abstract][Full Text] [Related]
30. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685 [TBL] [Abstract][Full Text] [Related]
31. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500 [TBL] [Abstract][Full Text] [Related]
32. Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. Huang XC; Sun YL; Salim AA; Chen ZS; Capon RJ Biochem Pharmacol; 2013 May; 85(9):1257-68. PubMed ID: 23415901 [TBL] [Abstract][Full Text] [Related]
33. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183 [TBL] [Abstract][Full Text] [Related]
34. Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Li S; Lei Y; Jia Y; Li N; Wink M; Ma Y Phytomedicine; 2011 Dec; 19(1):83-7. PubMed ID: 21802927 [TBL] [Abstract][Full Text] [Related]
35. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib. Graber-Maier A; Gutmann H; Drewe J Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289 [TBL] [Abstract][Full Text] [Related]
36. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054 [TBL] [Abstract][Full Text] [Related]
37. The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Ma Y; Wink M Phytother Res; 2010 Jan; 24(1):146-9. PubMed ID: 19548284 [TBL] [Abstract][Full Text] [Related]
38. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Imai Y; Ishikawa E; Asada S; Sugimoto Y Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404 [TBL] [Abstract][Full Text] [Related]
39. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610 [TBL] [Abstract][Full Text] [Related]
40. ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells. Mirzaei SA; Gholamian Dehkordi N; Ghamghami M; Amiri AH; Dalir Abdolahinia E; Elahian F Toxicol Appl Pharmacol; 2017 Dec; 337():22-29. PubMed ID: 29079042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]